Deciphering the neuroprotective signaling of SGLT2 inhibitors in Alzheimer's disease.
Kamihara T, Kato R, Morisaki A, Kaneko S, Omura T, Shimizu A.
BackgroundAlzheimer's disease (AD) currently lacks fundamental curative treatments. While epidemiological evidence increasingly links sodium-glucose cotransporter 2 (SGLT2) inhibitors to reduced AD risk, the underlying molecular mechanisms remain poorly unders...